TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05937919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous injection of 68Ga-PMD22
Description: 68Ga-PMD22 were intravenous injected into the patients before PET/CT scans

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous injection of 68Ga-PMD22
Description: 68Ga-PMD22 were intravenous injected into the patients before PET/CT scans
Study: NCT05802602

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Porcine Collagen Membrane
Description: Atraumatic tooth extraction with porcine collagen membrane placement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bovine Collagen Dressing
Description: Atraumatic tooth extraction with bovine collagen dressing placement
Study: NCT05388565

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Domestic Violence Enhanced Perinatal Care Program
Description: Our intervention consists of four major components: a) information about IPV and its effects on maternal and infant health, b) danger assessment, c) options and safety plan, and d) resources.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Usual perinatal care (e.g., prenatal health education) and a list of resource information (e.g., crisis lines, local IPV and mental health resources)
Study: NCT06234735

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity in the community
Description: Supervised and guided PA sessions in the community setting using public resources such as parks, sports facilities, etc.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional intervention
Description: Conventional protocol for lung cancer and PA recommendations.
Study: NCT04683198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: camrelizumab
Description: Camrelizumab intravenous infusion was administered at a dose of 200 mg on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/6) and maintenance phase ,until PD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: Apatinib capsules 250 mg given orally , once daily in 21-day cycle and maintenance phase,until PD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/6).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide intravenous infusion was administered at a dose of 100 mg/m\^2 on Days 1, 2, and 3 of each 21-day cycle during the induction phase (Cycles 1-4/6).
Study: NCT05787353

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise programme
Description: Both protocols consisted of aerobic, breathing and flexibility exercises. Hospital-based CPR: three or four days per week for a total of 20 sessions. Home-based CPR: three or four days/a week over a period of six weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise programme
Description: Both protocols consisted of aerobic, breathing and flexibility exercises. Hospital-based CPR: three or four days per week for a total of 20 sessions. Home-based CPR: three or four days/a week over a period of six weeks.
Study: NCT06290895

Intervention type: OTHER
Intervention: women having had a second IVF cycle with AOA
Description: The absence of synergy between the oocyte and sperm leads to a negative impact on oocyte activation. Physiological oocyte activation requires a sperm-derived enzyme called phospholipase C zeta to cause the release of calcium in the form of oscillations from internal storages.
Study: NCT04730986

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ED GOAL Nursing
Description: A brief (\<7minutes) interview by an emergency department nurse to empower patients to formulate and communicate their goals for medical care with patients' outpatient clinicians.
Study: NCT06367868

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: After 5 ml CSF Drainage
Description: Optic Nerve Sheath Diameter and Intracranial Pressure measurements will be after 5 ml CSF drainage
Study: NCT05811494

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lexo
Description: Lexo is a Robot-Assited Gait device based on an end-effector system that supports the weight of the patient and help him to recover the walking function.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lokomat
Description: Lokomat is a Robot-Assited Gait device based on a fixed exoskeleton that supports the weight of the patient and help him to recover the walking function guiding the hips, knees and feet of the patient while walking.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-Mill
Description: C- Mill is a body weight support treadmill which includes virtual reality. I can provide feedback to the patient, assisting or hindering the gait task.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Body-weight support treadmill
Description: Body-weight support treadmill group will receive the same time and intensity of training like the robotic groups but using the treadmill
Study: NCT03797040

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell therapy
Description: PLX-R18: Allogeneic ex vivo expanded placental stromal cells
Study: NCT04901403

Intervention type: OTHER
Group type: OTHER
Intervention: Education
Description: Parents will be provided with information about Earned Income Tax Credits and budgeting

Intervention type: OTHER
Group type: OTHER
Intervention: Home visiting
Description: Parents as Teachers home visiting program

Intervention type: OTHER
Group type: OTHER
Intervention: Home visiting
Description: Parents as Teachers home visiting program
Study: NCT05535127

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Palpation with  laryngeal handshake technique
Description: Information alredy included

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Palpation strategy plus sequential ultrasound
Description: Information alredy included

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Identification of the cricothyroid membrane with routine ultrasound
Description: Information alredy included
Study: NCT06032039

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone
Description: Standard treatment for osteoarthritis knee pain

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Rich Plasma
Description: Alternative treatment for osteoarthritis knee pain
Study: NCT05961436

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PENG block
Description: Using ultrasound-guided technique, a total of 20ml of 0.25 % bupivacaine will be injected after negative aspiration.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FN block
Description: Using ultrasound-guided technique, after negative aspiration, 20 mL of 0.25 % bupivacaine will be administered.
Study: NCT05267054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ociperlimab
Description: administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ociperlimab
Description: administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: administered intravenously
Study: NCT06534411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide
Description: Participants will receive once-weekly cagrilintide subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will receive once-weekly semaglutide subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Participants will receive once-weekly tirzepatide subcutaneously.
Study: NCT04659408

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multistrain probiotic preparation
Description: One sachet daily, containing 3 grams of the freeze-dried multispecies probiotic Bactosan for a period of four weeks. One sachet will be mixed with 50-100 ml water and taken daily before breakfast or dinner. Bactosan contains the following eight bacterial strains: Bifidobacterium lactis W51, Bifidobacterium lactis W52, Enterococcus faecium W54, Lactobacillus acidophilus W22, Lactobacillus paracasei W20, Lactobacillus plantarum W21, Lactobacillus salivarius W24 and Lactococcus lactis W19, with a total viable cell count of 1 × 109 cfu/gram, and therefore 3 × 109 cfu/daily dose.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multistrain probiotic preparation
Description: One sachet daily, containing 3 grams of the freeze-dried multispecies probiotic Bactosan for a period of four weeks. One sachet will be mixed with 50-100 ml water and taken daily before breakfast or dinner. Bactosan contains the following eight bacterial strains: Bifidobacterium lactis W51, Bifidobacterium lactis W52, Enterococcus faecium W54, Lactobacillus acidophilus W22, Lactobacillus paracasei W20, Lactobacillus plantarum W21, Lactobacillus salivarius W24 and Lactococcus lactis W19, with a total viable cell count of 1 × 109 cfu/gram, and therefore 3 × 109 cfu/daily dose.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oat Bran
Description: 5 grams (one teaspoon) daily of the oat bran together with a meal of preference. The oat bran can be added to the usual breakfast cereal, yoghurt, pancakes, juice, milk, salad sauce or in an omelette.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oat Bran
Description: 5 grams (one teaspoon) daily of the oat bran together with a meal of preference. The oat bran can be added to the usual breakfast cereal, yoghurt, pancakes, juice, milk, salad sauce or in an omelette.
Study: NCT05763719

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rabbits for Resilience (RFR) + HIKA
Description: Economic empowerment program using animal husbandry for young adolescents and healthy relationship program for parents/couples in same household

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rabbits for Resilience (RFR) only
Description: Economic empowerment program using animal husbandry with young adolescents

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIKA Healthy Relationship Program
Description: Healthy relationship program for parents/couples
Study: NCT06013475

Intervention type: DRUG
Intervention: Apalutamide
Description: Decision by the treating physician

Intervention type: DRUG
Intervention: Darolutamide (BAY 1841788)
Description: Decision by the treating physician

Intervention type: DRUG
Intervention: Enzalutamide
Description: Decision by treating physician
Study: NCT05281562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza
Description: Daily dose of 1.68grams omega-3 fatty acids, 2 Lovaza pills per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Arginine Powder
Description: Daily dose of 4.5 grams L-Arginine, powder form.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Daily dose of 500 mg Vitamin C, powder form.
Study: NCT06243770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mRNA-0184
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mRNA-0184
Description: Intravenous infusion
Study: NCT05024760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: Chlorhexidine will be inserted into the dental implant internal cavity during dental implant insertion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrogen Peroxide
Description: Hydrogen Peroxide will be inserted into the internal cavity of the dental implant during dental implant insertion.
Study: NCT06409949

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Walking assessment
Description: Participating patients will undergo the following evaluations at baseline and after six months of treatment with MitoQ or placebo:~Assessment of walking impairment: Evaluation of treadmill maximum walking distances, six-minute walking distance, and daily physical activity (average steps taken daily)
Study: NCT06060392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Pill
Description: Patient will receive oral semaglutide
Study: NCT05844137

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NAFLD Education
Description: NAFLD Education
Study: NCT05095597

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Injection of hUC-PRP by hysteroscopy
Description: PRP previously frozen at -80ºC (6±2 mL) will be defrozen after checking donor-receptor compatibility and viral safety study. PRP (4±2 mL) will be activated with 5% CaCl2 and immediately injected (4±2 mL) in the sub-endometrial wall via hysteroscopy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection of hUC-PRP by hysteroscopy
Description: PRP previously frozen at -80ºC (6±2 mL) will be defrozen after checking donor-receptor compatibility and viral safety study. PRP (4±2 mL) will be activated with 5% CaCl2 and immediately injected (4±2 mL) in the sub-endometrial wall via hysteroscopy.

Intervention type: DRUG
Group type: OTHER
Intervention: Oestraclin
Description: Patients will receive estrogenic therapy, based on estradiol, for 10±2 days (oestraclin, topical cream, 5µg daily for 10±2 days).

Intervention type: DRUG
Group type: OTHER
Intervention: Oestraclin
Description: Patients will receive estrogenic therapy, based on estradiol, for 10±2 days (oestraclin, topical cream, 5µg daily for 10±2 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oestraclin
Description: Patients will receive estrogenic therapy, based on estradiol, for 10±2 days (oestraclin, topical cream, 5µg daily for 10±2 days).
Study: NCT06035276

Intervention type: OTHER
Group type: OTHER
Intervention: Exposure to clean air
Description: Subjects will be exposed to filtered indoor air (clean air) for 4 hours in the Fraunhofer Environmental Exposure Chamber. The chamber can accommodate up to 18 subjects, is ventilated by HEPA-filtered and conditioned air, ensuring a constant humidity (40 ± 10%), temperature (22 ± 2°C), and airflow (1500 ± 100 m3/hr). During exposure they will perform an intermittent bicycle ergometer activity at 50 W for 10 minutes alternating with 20 minutes rest.

Intervention type: OTHER
Group type: OTHER
Intervention: Exposure to clean air
Description: Subjects will be exposed to filtered indoor air (clean air) for 4 hours in the Fraunhofer Environmental Exposure Chamber. The chamber can accommodate up to 18 subjects, is ventilated by HEPA-filtered and conditioned air, ensuring a constant humidity (40 ± 10%), temperature (22 ± 2°C), and airflow (1500 ± 100 m3/hr). During exposure they will perform an intermittent bicycle ergometer activity at 50 W for 10 minutes alternating with 20 minutes rest.

Intervention type: OTHER
Group type: OTHER
Intervention: Exposure to urban air
Description: Subjects will be brought to a traffic dense urban region (urban air) with high traffic density and increased levels of particulate matter and vehicle emissions. Subjects will stay in this area for 4 hours. During exposure, all subjects will walk together with study staff. Rest periods are only allowed outside. Intervals of activity and rest will be similar to the clean air regimen.
Study: NCT05844137

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet/lifestyle support
Description: diet/lifestyle support

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T2D medication management
Description: T2D medication management
Study: NCT05095597

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Umbilical cord blood collection
Description: The SCU will be collected using a blood collection bag containing anticoagulant. This step will be performed by the medical and nursing staff of the obstetrics service of the HUP La Fe. The blood collection bags will be the following, or similar: Cord Blood Collection Bags from MACOPHARMA; CPD Umbilical Cord Bag from GRIFOLS.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endometrial biopsy
Description: Biopsies will be taken by specialized medical personnel by aspiration with an intrauterine cannula (pipelle or cornier). Samples will be collected in 15 mL tubes (or in a larger capacity container if needed) containing PBS or RNA later until frozen at -80ºC, at the IVI Foundation facilities. Prior to freezing (in a 1.8-2 mL cryotube) the PBS will be removed and the sample cleaned in a Petri dish if needed.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endometrial biopsy
Description: Biopsies will be taken by specialized medical personnel by aspiration with an intrauterine cannula (pipelle or cornier). Samples will be collected in 15 mL tubes (or in a larger capacity container if needed) containing PBS or RNA later until frozen at -80ºC, at the IVI Foundation facilities. Prior to freezing (in a 1.8-2 mL cryotube) the PBS will be removed and the sample cleaned in a Petri dish if needed.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endometrial biopsy
Description: Biopsies will be taken by specialized medical personnel by aspiration with an intrauterine cannula (pipelle or cornier). Samples will be collected in 15 mL tubes (or in a larger capacity container if needed) containing PBS or RNA later until frozen at -80ºC, at the IVI Foundation facilities. Prior to freezing (in a 1.8-2 mL cryotube) the PBS will be removed and the sample cleaned in a Petri dish if needed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial biopsy
Description: Biopsies will be taken by specialized medical personnel by aspiration with an intrauterine cannula (pipelle or cornier). Samples will be collected in 15 mL tubes (or in a larger capacity container if needed) containing PBS or RNA later until frozen at -80ºC, at the IVI Foundation facilities. Prior to freezing (in a 1.8-2 mL cryotube) the PBS will be removed and the sample cleaned in a Petri dish if needed.
Study: NCT05844137

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: clinically-indicated liver testing and care
Description: clinically-indicated liver testing and care
Study: NCT05158465

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Intervention will include 3 one-on-one motivational interviewing sessions and 3 follow-up calls with a trained MI health educator. These sessions aim to promote better oral hygiene and oral health.
Study: NCT06035276

Intervention type: OTHER
Group type: OTHER
Intervention: Exposure to urban air
Description: Subjects will be brought to a traffic dense urban region (urban air) with high traffic density and increased levels of particulate matter and vehicle emissions. Subjects will stay in this area for 4 hours. During exposure, all subjects will walk together with study staff. Rest periods are only allowed outside. Intervals of activity and rest will be similar to the clean air regimen.
Study: NCT06223542

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT06071195

Intervention type: DIAGNOSTIC_TEST
Intervention: Prostate Cancer Patients
Description: see arm/group description
Study: NCT06409949

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Walking assessment
Description: Participating patients will undergo the following evaluations at baseline and after six months of treatment with MitoQ or placebo:~Assessment of walking impairment: Evaluation of treadmill maximum walking distances, six-minute walking distance, and daily physical activity (average steps taken daily)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: QOL Survey
Description: Assessment of quality of life: Survey of Quality of life with the Walking Impairment Questionnaire and Short Form 36

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: QOL Survey
Description: Assessment of quality of life: Survey of Quality of life with the Walking Impairment Questionnaire and Short Form 36
Study: NCT04775407

Intervention type: PROCEDURE
Intervention: blood sampling
Description: IgM og IgG analysis
Study: NCT06223542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UAE Inhibitor TAK-243
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UAE Inhibitor TAK-243
Description: Given IV
Study: NCT06645197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNUG01
Description: Recombinant adeno-associated virus serotype 9 capsid containing human SG001 expression cassette
Study: NCT06565052

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation Program
Description: A hybrid-based, prehabilitation regimen comprised of nutritional optimization (multivitamin and protein supplement shake) and virtual, aerobic and resistance exercise sessions with clinical exercise physiologists. Virtual exercise sessions will be performed via a HIPAA-compliant videoconferencing platform or by phone call. Mini-exercise cycle ergometer, dumbbells, and resistance bands will be provided and delivered to participant. Heart rate monitors and wi-fi enable tablet will be provided if needed.
Study: NCT06409949

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Ankle pressure at rest and after stress
Description: Assessment of leg hemodynamics: Evaluation of post-occlusive ankle pressure and ankle/brachial index

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Ankle pressure at rest and after stress
Description: Assessment of leg hemodynamics: Evaluation of post-occlusive ankle pressure and ankle/brachial index